IFx-2.0

About TuHURA Biosciences

TuHURA Biosciences is a Phase 3 immuno-oncology company with a mission to develop therapeutics that overcome primary and acquired resistance to cancer immunotherapies. Founded in 2019, the company has aggressively built a diversified pipeline through internal R&D and the strategic 2025 acquisition of Kineta, Inc., which added the clinical-stage VISTA inhibitor TBS-2025. TuHURA's strategy focuses on accelerating development via regulatory pathways for unmet needs in both solid tumors (e.g., Merkel cell carcinoma) and hematological cancers (e.g., AML), aiming to broaden the efficacy of existing treatments like checkpoint inhibitors.

Therapeutic Areas